Exciva: Funding, Investors & Team (Oct 2026)
Exciva develops clinical-stage biopharmaceutical therapies focused on addressing neuropsychiatric symptoms associated with dementia, including agitation and aggression in Alzheimer’s disease. It applies a targeted drug rescue approach that identifies and repurposes previously approved or clinically tested compounds into new therapeutic candidates. Exciva conducts scientific research and clinical studies to evaluate safety and potential effectiveness of its investigational products in neuropsychiatry. Its programs include formulations and methods designed for symptomatic relief and improved behavioral outcomes. Exciva collaborates with scientific and medical professionals to advance its pipeline through regulated trial phases and regulatory processes.
Exciva has raised $59.4M across 1 funding round on record, the most recent a Series B of $59.4M announced in Jan 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Exciva Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Exciva Funding Rounds
Exciva Founders and Leadership Team
No contact details are on record for this team yet.
Exciva Funding Compared to Other Biotechnology Startups
Exciva's latest round of $59.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Exciva in Biotechnology and Heidelberg
Companies Similar to Exciva
Artcline is a biotech company that creates diagnostic and therapeutic techniques for critical care medicine.
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug…
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of…
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and…
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is…
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and…
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their…
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored…
Exciva Funding FAQs
What does Exciva do?
Exciva develops clinical-stage biopharmaceutical therapies focused on addressing neuropsychiatric symptoms associated with dementia, including agitation and aggression in Alzheimer’s disease. It applies a targeted drug rescue approach that identifies and repurposes previously approved or clinically tested compounds into new therapeutic candidates. Exciva conducts scientific research and clinical studies to evaluate safety and potential effectiveness of its investigational products in neuropsychiatry. Its programs include formulations and methods designed for symptomatic relief and improved behavioral outcomes. Exciva collaborates with scientific and medical professionals to advance its pipeline through regulated trial phases and regulatory processes.
How much funding has Exciva raised?
Exciva has raised $59.4M across 1 round on record. The most recent is a Series B of $59.4M announced in Jan 2026.
When did Exciva last raise funding?
Exciva's most recent funding round on record is a Series B of $59.4M, announced in Jan 2026.
Who founded Exciva?
FundedIQ lists Anton Bespalov (Founder) at Exciva.
Where is Exciva headquartered?
Exciva is based in Heidelberg, Baden-Wurttemberg, Germany.
How many employees does Exciva have?
Exciva is in the 1-10 employee band.
How does Exciva's funding compare to other Biotechnology startups?
Exciva's latest round of $59.4M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Exciva Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Exciva is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.